Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00973752 | Treatment of Older Adults With Acute Lymphoblastic Leukemia | PHASE2 | COMPLETED | 30 | — | — | Aug 1, 2009 | Apr 1, 2016 | Mar 30, 2017 | 3 | United States |
The number of participants alive one year after baseline.
| Arm | Type | Description |
|---|---|---|
| Experimental | EXPERIMENTAL | All patients treated on same arm |
| Name | Type | Description |
|---|---|---|
| Prednisone | DRUG | Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy. |
| Vincristine | DRUG | Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy |
| Doxorubicin | DRUG | Intravenously during Induction, CNS, and Consolidation 2 therapy |
| PEG-asparaginase | DRUG | Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy |
| Cytarabine | DRUG | Intrathecally during Induction and CNS therapy |
| Methotrexate | DRUG | Intrathecally during Induction, CNS, and Continuation Therapy |
| Imatinib | DRUG | Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy |
| Clofarabine | DRUG | Intravenously during Consolidation 1 Therapy |
| 6 Mercaptopurine | DRUG | Orally during CNS, Consolidation 2 and Continuation Therapy |
Inclusion Criteria: * Acute lymphoblastic leukemia, excluding known mature B-cell ALL by the presence of any of the following: surface immunoglobulin, L3 morphology, t(8;14)(q24;q32), t(8;22), or t(2;8). * Patients with mature B-cell ALL will be removed from the protocol as soon as the diagnosis is...